# US 2026/0098034 A1 · 2h-benzotriazole derivative, preparation method therefor, and pharmaceutical composition containing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098034 A1
- Document ID: US20260098034A1
- Status: Published application
- Kind: A1
- Application number: 19/112,922
- Filed: 2023-08-23
- Published: 2026-04-09
- Earliest claimed: 2022-09-19
- Assignees: ORxes Therapeutics Co., Ltd.
- Applicants: Orxes Therapeutics Co., Ltd.
- Inventors: Peng WANG; Yuqing ZHAO; Yan ZHOU; Lirong ZHANG; Jie ZHOU; Xin ZHOU
- Web page: https://patentgrep.com/patent/US20260098034A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention discloses a benzisothiazole compound as well as a pharmaceutical composition and application thereof, belongs to the technical field of medicines, and particularly relates to a 2H-benzotriazole substituted benzisothiazole compound with a novel structure as shown in a formula (I), a pharmaceutical composition containing the compound and application of the compound in preparation of medicines for treating and/or preventing premature ejaculation. Through in-vivo activity test research, the compound has obviously higher anti-premature ejaculation activity than the on-sale drug dapoxetine.

## Claims

### Claim 1

A 2H-benzotriazole derivative or a pharmaceutically acceptable salt thereof, characterized in that the structure of the derivative is as shown by formula (I):
wherein
X represents: a C3-C4-alkyl or a C3-C4-alkoxy;
Y represents: CH or N;
Z represents: O or S;
R represents: optional substitution of hydrogen atom(s) by 1-3 halogen atoms selected from the group consisting of fluorine, chlorine, bromine.

### Claim 2 (depends on 1)

The 2H-benzotriazole derivative or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that the 2H-benzotriazole alkyl derivative is any one of the following compounds:
A001: 1-(4-(4-benzoisoxazolyl) piperazin-1-yl) butyl-2H-benzotriazole
A002: 1-(3-(4-(3-(6-fluorobenzoisoxazolyl)) piperidin-1-yl) propyl-2H-benzotriazole
A003: 1-(4-(4-(3-(6-fluorobenzoisoxazolyl)) piperidin-1-yl) butyl-2H-benzotriazole
A004: 1-(3-(4-benzisothiazolyl) piperazin-1-yl) propyl-2H-benzotriazole
A005: 1-(3-(4-(3-(6-fluorobenzoisoxazolyl)) piperazin-1-yl) propyl-2H-benzotriazole
A006: 1-(4-(4-(3-(6-fluorobenzoisoxazolyl)) piperazin-1-yl) butyl-2H-benzotriazole.

### Claim 3 (depends on 1)

A pharmaceutical composition, characterized in that the pharmaceutical composition comprises any one or more of the 2H-benzotriazole derivatives or a pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, characterized in that the dosage form of the pharmaceutical composition is selected from tablets, sprays, oral soluble film agents, powders, capsules, and injections; and the content of active ingredient in the dosage form is 0.1% to 99.5%.

### Claim 5 (depends on 1)

A method of treating and/or preventing premature ejaculation, the method comprising administering the 2H-benzotriazole derivative or a pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof.

### Claim 6 (depends on 3)

A method of treating and/or preventing premature ejaculation, the method comprising administering the pharmaceutical composition according to claim 3 to a subject in need thereof.

### Claim 7 (depends on 1)

A method for preparing the 2H-benzotriazole derivative or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that the method comprises the following synthetic scheme:

### Claim 8 (depends on 2)

A pharmaceutical composition, characterized in that the pharmaceutical composition comprises any one or more of the 2H-benzotriazole derivatives or a pharmaceutically acceptable salt thereof according to claim 2, and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 2)

A method of treating and/or preventing premature ejaculation, the method comprising administering the 2H-benzotriazole derivative or a pharmaceutically acceptable salt thereof according to claim 2 to a subject in need thereof.

### Claim 10 (depends on 4)

A method of treating and/or preventing premature ejaculation, the method comprising administering the pharmaceutical composition according to claim 4 to a subject in need thereof.
